APA (7th ed.) Citation

Markus Ramste, Markus Ritvos, Sergei Häyrynen, Johanna I. Kiiski, Mikko Niemi, & Juha Sinisalo. (2023). CYP2C19 loss‐of‐function alleles and use of omeprazole or esomeprazole increase the risk of cardiovascular outcomes in patients using clopidogrel. Wiley.

Chicago Style (17th ed.) Citation

Markus Ramste, Markus Ritvos, Sergei Häyrynen, Johanna I. Kiiski, Mikko Niemi, and Juha Sinisalo. CYP2C19 Loss‐of‐function Alleles and Use of Omeprazole or Esomeprazole Increase the Risk of Cardiovascular Outcomes in Patients Using Clopidogrel. Wiley, 2023.

MLA (9th ed.) Citation

Markus Ramste, et al. CYP2C19 Loss‐of‐function Alleles and Use of Omeprazole or Esomeprazole Increase the Risk of Cardiovascular Outcomes in Patients Using Clopidogrel. Wiley, 2023.